# MicroTransponder

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microtransponder

- Industry: Medical Devices & Equipment
- Headquarters: Austin, US
- Website: www.microtransponder.com
- Total disclosed funding: $105M
- Latest round: Series F (Mar 5, 2025)
- Investors on record: 9

## About

MicroTransponder, Inc. is a medical technology company focused on enhancing recovery for patients with chronic neurological conditions through innovative solutions, particularly for those recovering from ischemic strokes.Founded in 2007 in Austin, US, MicroTransponder, Inc. specializes in medical devices that assist in rehabilitation for neurological patients. The firm has raised a total of USD 32.50 mn in funding, with the latest funding round being Series F on March 5, 2025, led by US Venture Partners, alongside other investors. The company was founded by Jordan Curnes and currently operates under the leadership of CEO Jean-Philippe Allar and Richard Foust.MicroTransponder Inc. specializes in innovative medical technology aimed at enhancing the rehabilitation of patients with chronic neurological conditions, particularly those affected by ischemic stroke. Their flagship product, the Vivistim® Paired VNS™ System, integrates Vagus Nerve Stimulation (VNS) with rehabilitation therapy to significantly improve upper extremity motor function in chronic stroke patients. Approved by the FDA, the Vivistim System is designed specifically for individuals seeking to regain motor abilities in their arms and hands, often years after experiencing a stroke. The product's utilization is rooted in three key principles: increased neuromodulation, high repetition therapy, and self-activation/portability. MicroTransponder's offerings are primarily targeted at healthcare facilities and rehabilitation centers across the United States and select European markets, catering to a diverse client base, including healthcare professionals and patients with moderate to severe arm impairment.The revenue model of MicroTransponder Inc. is structured around the sale of its Vivistim System and associated therapeutic services, which are typically transacted through partnerships with healthcare providers and rehabilitation centers. These transactions often involve direct sales agreements where healthcare institutions purchase the equipment and integrate it into their rehabilitation programs. Additionally, the company may engage in training and support services for medical professionals, enhancing the effectiveness of the Vivistim System in clinical settings. While specific pricing details for the Vivistim System and related services are not disclosed, the company positions itself within the medical device market, suggesting that transaction structures likely reflect standard practices within this sector, including direct sales to clinics and hospitals.In March 2025, MicroTransponder, Inc. raised USD 32.50 mn in Series F funding, led by US Venture Partners, with participation from other investors. The company plans to use this funding to expand operations and enhance its development efforts. It is also focused on launching new products aimed at further improving rehabilitation outcomes for stroke patients and is exploring expansion into additional markets, particularly in Europe, by the end of 2025.

## Funding rounds

- Series F, Mar 5, 2025, $33M — US Venture Partners, Gilde Healthcare, Vertical Group, Longitude Capital, Action Potential Venture Capital, Green Park & Golf Ventures, Osage Venture Partners, Exceller Hunt - Family Office
- Series E, Sep 21, 2022, $30M — US Venture Partners, OUP (Osage University Partners), Vertical Group, Action Potential Venture Capital, Green Park & Golf Ventures, Exceller Hunt - Family Office
- Series E, Jun 3, 2022, $43M — US Venture Partners, OUP (Osage University Partners), Vertical Group, Action Potential Venture Capital, Green Park & Golf Ventures, Exceller Hunt - Family Office

## Investors

- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series E, Series F
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series E
- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Series E, Series F
- Action Potential Venture Capital (https://capitalatlas.ai/funds/action-potential-venture-capital) — Series E, Series F
- Green Park & Golf Ventures (https://capitalatlas.ai/funds/green-park-golf-ventures) — Series E, Series F
- Exceller Hunt - Family Office — Series E, Series F
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series F
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series F
- Osage Venture Partners (https://capitalatlas.ai/funds/osage-venture-partners) — Series F